XORTX Announces Closing of US$1.1 Million Registered Direct Offering [Canadian Business Journal (Canada)]
XORTX Therapeutics Inc. (XRTX)
Company Research
Source: Canadian Business Journal
CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“CompanyCommon SharesPre-Funded WarrantsOfferingIn connection with the Offering, the Company entered into a definitive securities purchase agreement with an institutional investor pursuant to which the Company has issued 572,470 Common Shares and 1,117,530 Pre-Funded Warrants. Each Pre-funded Warrant will entitle the holder to acquire one common share at an exercise price of $0.001 per share.The gross proceeds from the Offering were US$1,102,500.00, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.D. Boral Capital LLC acted as sole placement agent for the Offering, and will be issued 87,500 agent warrants. Each agent warrant is exercisable into one Common Share of the Company at an exercise price of US$0.69 per Common Share commencing 181 days following issua
Show less
Read more
Impact Snapshot
Event Time:
XRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XRTX alerts
High impacting XORTX Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
XRTX
News
- XORTX Therapeutics Says Published Research Supports Company Approach to Gout Treatment [Yahoo! Finance]Yahoo! Finance
- XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update [Canadian Business Journal (Canada)]Canadian Business Journal
- XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
- XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate UpdateGlobeNewswire
- XORTX Announces Closing of US$1.1 Million Registered Direct OfferingGlobeNewswire
XRTX
Sec Filings
- 1/2/26 - Form 6-K
- 11/17/25 - Form 6-K
- 10/31/25 - Form 6-K
- XRTX's page on the SEC website